Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:004225510 | Cervix | CC | ribosome assembly | 25/2311 | 61/18723 | 1.70e-08 | 1.27e-06 | 25 |
GO:004227310 | Cervix | CC | ribosomal large subunit biogenesis | 26/2311 | 72/18723 | 1.87e-07 | 8.48e-06 | 26 |
GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
GO:002261810 | Cervix | CC | ribonucleoprotein complex assembly | 49/2311 | 220/18723 | 2.52e-05 | 4.29e-04 | 49 |
GO:000002710 | Cervix | CC | ribosomal large subunit assembly | 12/2311 | 27/18723 | 3.52e-05 | 5.65e-04 | 12 |
GO:007182610 | Cervix | CC | ribonucleoprotein complex subunit organization | 49/2311 | 227/18723 | 5.91e-05 | 8.54e-04 | 49 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:004225515 | Cervix | HSIL_HPV | ribosome assembly | 20/737 | 61/18723 | 8.44e-14 | 2.03e-10 | 20 |
GO:002261315 | Cervix | HSIL_HPV | ribonucleoprotein complex biogenesis | 52/737 | 463/18723 | 9.85e-12 | 6.81e-09 | 52 |
GO:004225415 | Cervix | HSIL_HPV | ribosome biogenesis | 40/737 | 299/18723 | 1.25e-11 | 6.81e-09 | 40 |
GO:004227315 | Cervix | HSIL_HPV | ribosomal large subunit biogenesis | 17/737 | 72/18723 | 1.94e-09 | 3.23e-07 | 17 |
GO:002261815 | Cervix | HSIL_HPV | ribonucleoprotein complex assembly | 29/737 | 220/18723 | 1.19e-08 | 1.30e-06 | 29 |
GO:007182615 | Cervix | HSIL_HPV | ribonucleoprotein complex subunit organization | 29/737 | 227/18723 | 2.42e-08 | 2.18e-06 | 29 |
GO:000002715 | Cervix | HSIL_HPV | ribosomal large subunit assembly | 9/737 | 27/18723 | 5.35e-07 | 2.77e-05 | 9 |
GO:00713533 | Cervix | HSIL_HPV | cellular response to interleukin-4 | 7/737 | 33/18723 | 2.48e-04 | 4.30e-03 | 7 |
GO:00706703 | Cervix | HSIL_HPV | response to interleukin-4 | 7/737 | 36/18723 | 4.38e-04 | 6.51e-03 | 7 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:0022618 | Colorectum | AD | ribonucleoprotein complex assembly | 92/3918 | 220/18723 | 1.49e-12 | 2.60e-10 | 92 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030106 | Colorectum | MSI-H | Ribosome | 87/797 | 167/8465 | 5.55e-46 | 1.80e-43 | 1.51e-43 | 87 |
hsa051716 | Colorectum | MSI-H | Coronavirus disease - COVID-19 | 91/797 | 232/8465 | 2.21e-35 | 3.58e-33 | 3.00e-33 | 91 |
hsa030107 | Colorectum | MSI-H | Ribosome | 87/797 | 167/8465 | 5.55e-46 | 1.80e-43 | 1.51e-43 | 87 |
hsa051717 | Colorectum | MSI-H | Coronavirus disease - COVID-19 | 91/797 | 232/8465 | 2.21e-35 | 3.58e-33 | 3.00e-33 | 91 |
hsa051718 | Colorectum | FAP | Coronavirus disease - COVID-19 | 78/1404 | 232/8465 | 9.94e-11 | 1.11e-08 | 6.73e-09 | 78 |
hsa030108 | Colorectum | FAP | Ribosome | 59/1404 | 167/8465 | 2.38e-09 | 1.32e-07 | 8.05e-08 | 59 |
hsa051719 | Colorectum | FAP | Coronavirus disease - COVID-19 | 78/1404 | 232/8465 | 9.94e-11 | 1.11e-08 | 6.73e-09 | 78 |
hsa030109 | Colorectum | FAP | Ribosome | 59/1404 | 167/8465 | 2.38e-09 | 1.32e-07 | 8.05e-08 | 59 |
hsa0301010 | Colorectum | CRC | Ribosome | 60/1091 | 167/8465 | 1.43e-14 | 2.78e-12 | 1.88e-12 | 60 |
hsa0517110 | Colorectum | CRC | Coronavirus disease - COVID-19 | 74/1091 | 232/8465 | 1.66e-14 | 2.78e-12 | 1.88e-12 | 74 |
hsa0301011 | Colorectum | CRC | Ribosome | 60/1091 | 167/8465 | 1.43e-14 | 2.78e-12 | 1.88e-12 | 60 |
hsa0517111 | Colorectum | CRC | Coronavirus disease - COVID-19 | 74/1091 | 232/8465 | 1.66e-14 | 2.78e-12 | 1.88e-12 | 74 |
hsa0301026 | Endometrium | AEH | Ribosome | 89/1197 | 167/8465 | 1.88e-33 | 6.09e-31 | 4.46e-31 | 89 |
hsa0517126 | Endometrium | AEH | Coronavirus disease - COVID-19 | 99/1197 | 232/8465 | 5.19e-27 | 3.37e-25 | 2.47e-25 | 99 |
hsa03010112 | Endometrium | AEH | Ribosome | 89/1197 | 167/8465 | 1.88e-33 | 6.09e-31 | 4.46e-31 | 89 |
hsa05171112 | Endometrium | AEH | Coronavirus disease - COVID-19 | 99/1197 | 232/8465 | 5.19e-27 | 3.37e-25 | 2.47e-25 | 99 |
hsa0301027 | Endometrium | EEC | Ribosome | 89/1237 | 167/8465 | 2.55e-32 | 8.39e-30 | 6.26e-30 | 89 |
hsa0517127 | Endometrium | EEC | Coronavirus disease - COVID-19 | 99/1237 | 232/8465 | 7.43e-26 | 4.89e-24 | 3.65e-24 | 99 |
hsa0301036 | Endometrium | EEC | Ribosome | 89/1237 | 167/8465 | 2.55e-32 | 8.39e-30 | 6.26e-30 | 89 |
hsa0517136 | Endometrium | EEC | Coronavirus disease - COVID-19 | 99/1237 | 232/8465 | 7.43e-26 | 4.89e-24 | 3.65e-24 | 99 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPLP0 | SNV | Missense_Mutation | | c.784N>A | p.Ala262Thr | p.A262T | P05388 | protein_coding | tolerated(0.05) | possibly_damaging(0.817) | TCGA-BH-A1FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPLP0 | insertion | In_Frame_Ins | novel | c.211_212insCTC | p.Asn71delinsThrHis | p.N71delinsTH | P05388 | protein_coding | | | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
RPLP0 | insertion | Frame_Shift_Ins | novel | c.210_211insCATTTTTCGTTCATGGA | p.Asn71HisfsTer77 | p.N71Hfs*77 | P05388 | protein_coding | | | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
RPLP0 | SNV | Missense_Mutation | rs563131457 | c.662A>G | p.Asn221Ser | p.N221S | P05388 | protein_coding | tolerated(0.08) | benign(0.022) | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RPLP0 | SNV | Missense_Mutation | novel | c.818N>G | p.Ser273Cys | p.S273C | P05388 | protein_coding | deleterious(0) | possibly_damaging(0.56) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RPLP0 | SNV | Missense_Mutation | novel | c.511G>A | p.Glu171Lys | p.E171K | P05388 | protein_coding | deleterious(0.03) | benign(0.048) | TCGA-AA-3514-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPLP0 | SNV | Missense_Mutation | novel | c.518N>T | p.Thr173Met | p.T173M | P05388 | protein_coding | deleterious(0.02) | benign(0.186) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPLP0 | SNV | Missense_Mutation | | c.409N>C | p.Phe137Leu | p.F137L | P05388 | protein_coding | deleterious(0.01) | benign(0.196) | TCGA-A5-A0GA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
RPLP0 | SNV | Missense_Mutation | rs766132340 | c.86N>C | p.Ile29Thr | p.I29T | P05388 | protein_coding | deleterious(0.01) | possibly_damaging(0.457) | TCGA-A5-A0R7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPLP0 | SNV | Missense_Mutation | | c.25T>C | p.Trp9Arg | p.W9R | P05388 | protein_coding | tolerated(0.41) | benign(0.02) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |